TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45
14 WEEK SSAC FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFBINARYMIX
Lock Date: 03/27/02
Cage Range: All
Reasons For Removal: 25017 Scheduled Sacrifice
Removal Date Range: 12/16/98 - 12/17/98
Treatment Groups: Include 001 0 NG / 0 UG
Include 002 10 NG / 10 UG
Include 003 100 NG /100 UG
Include 005 300 NG /300 UG
Include 007 1000 NG/1000 UG
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 86 98 98 98
Scheduled Sacrifice 16 10 16 16 16
Early Deaths
Survivors
Animals Examined Microscopically 10 10 10 10 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (10) (10) (10) (10) (10)
Fatty Change, Diffuse 1 [1.0] 6 [1.2]
Inflammation 10 [1.0] 10 [1.0] 10 [1.0] 10 [1.0] 10 [1.2]
Mixed Cell Focus 1 1 1
Necrosis 1 [1.0]
Pigmentation 4 [1.0] 5 [1.0] 8 [1.0]
Hepatocyte, Hypertrophy 4 [1.0] 3 [1.0] 6 [1.0] 10 [2.2]
Hepatocyte, Multinucleated 7 [1.0]
Pancreas (10) (10) (10) (10) (10)
Basophilic Focus 2
Acinus, Atrophy 1 [1.0] 1 [2.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (10) (10) (10) (10) (10)
Hypertrophy 1 [2.0] 1 [1.0] 1 [1.0]
Thyroid Gland (10) (10) (10) (10) (10)
Follicular Cell, Hypertrophy 3 [1.0] 3 [1.0] 4 [1.0] 8 [1.4] 9 [1.3]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (10) (10) (10) (10) (10)
Atrophy 4 [3.3] 2 [3.5] 4 [3.8] 3 [3.7] 3 [3.3]
Uterus (10) (10) (10) (10) (10)
Metaplasia, Squamous 2 [1.0] 1 [1.0] 3 [1.0] 1 [1.0] 1 [1.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Spleen (10)
Pigmentation 10 [1.1]
Thymus (10) (10) (10) (10) (10)
Atrophy 4 [1.0] 1 [1.0] 1 [2.0] 5 [1.2]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (10) (10) (10) (10) (10)
Hemorrhage 1 [1.0]
Inflammation 1 [1.0] 1 [1.0] 1 [1.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/
0 UG 10 UG 100 UG 300 UG 1000 UG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------